


## AT A GLANCE


### Key figures – 2<sup>nd</sup> quarter 2010

| EUR million                                                    | Pharma-<br>ceuticals | Chemicals | Corporate<br>and Other | Total   | Change<br>in % |
|----------------------------------------------------------------|----------------------|-----------|------------------------|---------|----------------|
| Total revenues                                                 | 1,564.4              | 643.6     | –                      | 2,208.0 | 15.6           |
| Gross margin                                                   | 1,297.2              | 393.5     | –                      | 1,690.8 | 21.5           |
| Research and development                                       | –302.2               | –36.5     | –0.1                   | –338.8  | –0.5           |
| Operating result                                               | 158.2                | 166.0     | 2.0                    | 326.2   | 76.8           |
| Exceptional items                                              | –                    | –         | –1.2                   | –1.2    | –              |
| Earnings before interest and tax (EBIT)                        | 158.2                | 166.0     | 0.8                    | 325.0   | 76.2           |
| EBIT before depreciation and amortization (EBITDA)             | 350.0                | 208.6     | 1.3                    | 559.9   | 38.4           |
| Return on sales in %<br>(ROS: operating result/total revenues) | 10.1                 | 25.8      | –                      | 14.8    |                |
| Free cash flow                                                 | 258.6                | 174.0     | –76.2                  | 356.4   | –              |
| Underlying free cash flow                                      | 258.6                | 174.0     | –72.7                  | 359.9   | –              |
| Underlying free cash flow on revenues (FCR) in %               | 16.5                 | 27.0      | –                      | 16.3    |                |

### Total revenues by quarter



### Operating result by quarter



## HIGHLIGHTS – 2<sup>nd</sup> QUARTER 2010

- Total revenues increase 16% to record EUR 2.2 billion
- Profit after tax jumps 70% to EUR 187 million
- Free cash flow improves to EUR 356 million from EUR 79 million
- Rebif® sales +4.0% to EUR 402 million; Erbitux® sales +23% to a record EUR 210 million
- Liquid Crystals revenues up 50% to a record EUR 284 million
- Guidance raised for 2010: operating result including Millipore +90%
- Millipore acquisition completed on July 14